To include your compound in the COVID-19 Resource Center, submit it here.

Integrelin antiplatelet agent: Began Phase III trial

Cor Therapeutics Inc. (CORR)

Read the full 44 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE